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Abstract 
Ambient temperature filter dried vaccine formulations have been proposed to simultaneously 
achieve thermostability and offer a ready-to-use immunisation device that combines reconstitution 
and injection. Vaccine concentration should be uniform at the point of injection, but the uniformity 
following direct reconstitution of filter-dried vaccines has not been reported. We present here a study 
of vaccine mixing and release following dissolution of filter-dried model protein and toxoid antigens 
within a single syringe, filter and needle unit. Release was better for filters made from glass than 
cellulose. Without additional mixing, uniformity was poor and only 41% of input protein was released 
from protein filter-dried onto glass fiber. In contrast, adding a simple glass bead and mixing by 
inversion, 100% release antigen solution was achieved, with uniform concentration at exit from the 
needle throughout a simulated injection. Adsorption onto alum adjuvant had no detectable effect on 
vaccine dissolution and mixing. The uniformity and yield of low doses of diphtheria and tetanus toxoid 
was also improved by mixing, albeit with a lower yield of 60-68%. We conclude that uniformity and 
mixing should be studied to ensure safety and efficacy of directly reconstituted filter-dried vaccine 
formulations. 
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1 Introduction 
A significant proportion of the cost of vaccination programs lies in safe refrigerated storage 
and distribution, and costs of trained healthcare professionals for administration. This has driven 
extensive research into drying and thermostabilisation technology for vaccines [1]. Traditionally 
freeze-dried vaccines still require refrigerated storage, although excipient optimization can achieve 
thermostable lyophilized vaccines [2]. Freeze-dried vaccines still require careful reconstitution and 
preparation prior to administration, typically reconstitution in a freeze-drying vial, followed by transfer 
to a syringe and needle for injection. Whilst the widespread use of liquid formulations distributed in 
pre-filled syringes for many common vaccines reduces staff time and skill level, liquid vaccine 
preparations are inevitably less stable than freeze-dried formulations, with solid formulations more 
stable and easier to handle [3, 4] because chemical (e.g. hydrolysis) and physical (e.g. foaming or 
aggregation) instability have far faster kinetics in aqueous form. Pre-filled syringes could be argued 
to be more expensive formulations than traditional lyophilized vials, but in reality freeze-drying is 
already a labour intensive and slow process constrained by capacity of industrial freeze-driers [3], 
and the processes used for manufacture of vaccines in pre-filled syringes are now well developed. 
Furthermore, lyophilized vaccine vials still require water for injection plus disposable syringe and 
needle, which whilst low-cost components, increase the complexity of the supply chain.  
The ideal vaccine formulation must therefore noat only be produced from low cost 
components, but must also have cost-effective scalable manufacturing process, and the simplest 
possible format for the end-user administrating the vaccine dose. To give the product stability and 
avoid cold-chain storage, this device would contain a dry physical form produced using a scalable 
drying method which maximises thermostability. Whilst alternatives to injection such as dried oral 
solid dosage forms [5] offer benefits, the overwhelming majority of current vaccines require injection. 
Reconstitution of dried vaccine to a liquid for injection therefore becomes an important engineering 
consideration. 
The cost of freeze-drying, and burden of cold-chain storage and complex preparation for 
administration has driven research into a range of novel formulations, and modelling has shown that 
thermostable vaccines would deliver significant improvements to the vaccine supply chain[6]. 
Multiple alternatives to freeze-drying have been explored, such as spray- or foam- drying [7]. A long-
established and intensively studied example is the use of ambient temperature drying to form an 
amorphous sugar glass from high glass transition temperature carbohydrates such as trehalose [8-
10]. This method has been combined with simplified formulation to deliver a thermostable, single-
component vaccine formulation and injection format that shows great promise [11, 12]. The vaccine 
is dried to form a sugar glass on a non-woven fibre filter substrate, which is then encased in a filter 
housing which is connected between a syringe filled with water for injection, and the needle [13, 14]. 
The sugar glass vaccine dissolves in flow as the syringe is depressed, and the dissolved vaccine 
injected directly into the patient. This approach is suitable to fragile live attenuated recombinant viral 
vaccines including modified vaccinia and adenovirus, which were preserved on the membranes for 
at least 6 months storage at high temperature (45°C) [13]. Similarly, hepatitis B vaccine dried onto 
filters are stable and immunogenic at 55°C for 7 weeks [9].  
As this highly promising “all-in-one” formulation is now being developed for use in new human 
vaccine products, we questioned if the dissolution characteristics of reconstitution from the filter has 
been studied in enough detail. The uniformity of any drug prior to injection into patients is critical to 
safe and controlled administration and function, and we wished to understand if this novel formulation 
can deliver a uniform concentration of reconstituted vaccine. Whilst fluid flow through the filter matrix 
will generate a degree of turbidity, and some mixing will occur between reconstitution from the filter 
and the end of the needle, there is no mechanism driving axial redistribution if flow is unidirectional 
from syringe, through filter, into needle.  
The filter units reported for thermostable filter-dried viral vaccines [13] are not freely available, 
and no design or specification has been published. Therefore, to study the efficiency of reconstitution 
from ambient temperature filter-dried vaccine formulations, we developed a simple model 
formulation using an unmodified plastic syringe, which made mixing and reconstitution easy to 
monitor and quantify. Likewise, complex and fragile live attenuated vaccines are expensive and 
challenging to visualize, making study of mixing and reconstitution unnecessarily complex. Tetanus 
and diphtheria toxins derived from Clostridium tetani and Corynebacterium diphtheriae, respectively 
are chemically inactivated to form toxoids that retain antigenic structure and potently induce a 
protective toxin-neutralizing immunity. Whilst very stable when compared to live attenuated whole 
viral vaccines, structure can still be lost on storage or during processing or formulation [15, 16] 
Toxoids such as tetanus toxoid are among the most heat-stable biological vaccine components. 
However, World Health Organisation (WHO) recommend that tetanus and diphtheria toxoids still 
require storage at 2-8°C for years, with reduced stability of months at 25°C and only weeks at 37°C 
[15]. In this initial proof-of-concept study, we opted to explore recovery and mixing using the simplest 
single-protein vaccine to permit simple visualisation, and therefore selected these two toxoids as a 
model to study reconstitution from filter-dried vaccines. 
We present here a pilot study of mixing following reconstitution of filter-dried protein antigens. 
We used an extremely simple and low-cost injection rig to explore the feasibility and effectiveness 
of active mixing within a syringe prior to injection. To permit not only precise quantitation of vaccine 
dissolution but also direct imaging of uniformity of vaccine solution, we studied fluorescently labelled 
protein and alum-adsorbed protein and diptheria and tetanus toxoid as model vaccine antigens. We 
found that the filter dried vaccine is unlikely to be mixed effectively following reconstitution by addition 
of water alone, and that additional mixing by addition of a glass bead combined with agitation not 
only increased uniformity of vaccine delivered, but increased the yield.  
 
2 Materials and Methods 
2.1 Materials 
To make fluorescent model protein antigen, BSA at >=2 mg/ml in 0.5 M of carbonate buffer (pH 9.5) 
and 10 mg/ml FITC in anhydrous dimethyl sulfoxide (DMSO) were combined a ratio of 80-160 µg 
FITC per mg of antibody. After incubation at room temperature for 1 hour, conjugates were purified 
by size-exclusion chromatography. BSA, FITC and Sephadex G-50 superfine were from Sigma-
Aldrich (Dorset UK). Phosphate buffer saline tablets (Sigma, Dorset UK) were dissolved in ultrapure 
water and ProClin 300 (Sigma, Dorset UK) was added as a preservative. Adjuvant adsorbed antigen 
was prepared following manufacturers direction, briefly Imject Alum (Thermo Fisher UK, Paisley UK) 
was added to FITC-BSA at a final volume ratio of alum to immunogen of 1:3, then mixed together 
for 30 minutes for efficient adsorption. Non-adsorbed diphtheria and non-adsorbed tetanus toxoid 
were used as model antigens in a simulated combined vaccine, and were obtained from the National 
Institute for Biological Standards and Control (NIBSC, Potters Bar, UK) as well as monoclonal and 
polyclonal antibodies for sandwich ELISA antigen quantitation; all were reconstituted following the 
supplier’s recommended method. Two types of filter were compared for filter drying of model vaccine 
antigens: cellulose filters were Whatman™ qualitative filter papers grade 1 (Cat No 1001-055) with 
180 µm thickness; glassfibre filters were grade 8964 with 429.3 µm thickness (Ahlstrom, Lyon, 
France). Glass beads for mixing were taken from 1.2mL Sodium Heparin S-Monovette® blood 
collection tubes (Sarsedt, Leicester UK).   
2.2 Preparation of ambient temperature dried model antigen filters and combined injection 
device 
A simple prototype combined injection device was made using two filter-dried vaccine antigen 
squares loaded into the barrel of a 2ml plastic disposable syringe (BD, Berkshire UK). To promote 
mixing, a 3mm diameter glass mixing bead taken from a Monovette® 1.2mL blood collection tube 
(Sarstedt; Leicester UK) was added with the filters (Fig. 1A). To make filter-dried antigen squares, 
10µL of fluorescein, fluorescent protein or antigen solution was added per 5mm square filter, and 
dried at ambient temperature (typically 20° C) in a petri dish until completely dry, which took a 
minimum of 1 hour (drying time was based on previous thermogravimetric studies of vaccine drying 
onto polymer films [17], and confirmed by kinetic analysis of mass loss). To establish methods and 
directly image reconstitution, 1mM sodium fluorescein solution was dried onto filters. This was 
followed by study of filters loaded with fluorescently labelled BSA, used as a model protein to more 
accurately reflect vaccine antigen dissolution. A 3.2mg/mL solution of BSA-FITC was found to be 
the lowest concentration suitable for quantitative imaging in the chamber. To determine if a real 
toxoid vaccine antigen behaved similarly to the high concentration of model protein used, both 
diphtheria and tetanus toxoids were diluted in ultrapure water to the lowest concentration that 
permitted quantitation by ELISA. A concentration of 4 lf/ml was selected for both toxoids mixed in a 
ratio of 1:1, and 10µL was pipetted on a 5x5 mm square of filter to yield 0.02 lf of diphtheria and 
tetanus toxoid per filter. Toxoid concentrations are presented in flocculation value per ml (lf/mL). 
When two filters in a syringe were reconstituted with 500 µl ultrapure water, the maximum 
concentration of reconstituted vaccine expected was 0.08 lf/mL. 
2.3 Measurement of mixing and dissolution of filter dried model vaccine antigens 
To observe fluorescent protein mixing directly after reconstitution, filters with dried 1mM sodium 
fluorescein were imaged in a dark box using blue light excitation through an amber acrylic emission 
filter (IOrodeo, San Diego, USA) using a Canon S120 digital camera using manual aperture and 
exposure control. To observe fluorescent protein concentration delivered through the needle during 
a simulated vaccine injection, a chamber was made between a black acrylic and a clear 
polycarbonate sheet using two layers of pressure-sensitive adhesive tape to form a 0.2 mm gap (Fig 
2A). The tape was cut to form a shape that allowed the solution to be imaged within a 20µL 2 mm 
high and 10 mm long rectangular space immediately after leaving the needle. Following addition of 
0.5 mL water with or without mixing, the syringe was attached to a 25 mm long 23 Gauge needle, 
bent through 90 degrees and connect to the imaging chamber. As the syringe plunger was 
depressed the chamber was imaged using the camera, dark box, and excitation source plus 
emission filter described above. The syringe barrel was imaged to define volume delivered. A dried 
filter with standard dose of fluorescein was included beside the chamber to permit comparison of 
intensity between different tests; in all tests the intensity of this standard sample was equal, 
confirming excitation intensity and camera sensitivity was reproducible. All videos and images were 
processed to evaluate uniformity and concentration of released protein using ImageJ [18].  
After the syringe was completely emptied the total yield of model antigen in the ~0.5mL solution 
delivered was measured using three methods. Firstly, release of BSA-FITC with or without 
adsorption onto alum was measured using protein determination with the Pierce 660 nm Protein 
Assay following manufactures instructions. Briefly, 10 µL samples were mixed with 150 µl of Pierce 
660 Protein Assay Reagent (Thermo Fisher Scientific) in a microplate, and after incubation at a room 
temperature for 5 minutes the absorbance at 660 nm recorded and compared to a standard curve 
prepared from known BSA or FITC-BSA samples. When adsorbed onto alum adjuvant, protein 
concentrations were calculated from a standard curve of alum-adsorbed BSA. Secondly, absorbance 
at 495 was measured in parallel to determine fluorescein concentration; the release profiles were 
very similar to that observed for protein content. Thirdly, total antigen release from filter-dried toxoid 
squares was measured by sandwich ELISA using reported protocols for diphtheria [19] and tetanus 
[20] with modified blocking (2% BSA) and substrate (SigmaFast OPD; Sigma, Dorset UK). The anti-
diphtheria monoclonal capture antibody was NIBSC code: 10/130, and guinea pig polyclonal 
detection antibody was NIBSC code: 10/128. For tetanus, monoclonal capture antibody was NIBSC 
code: 10/134 and guinea pigs polyclonal detection antibody was NIBSC code: 10/132. Where 
indicated, a two-sample students t-test was used to assess statistical significance, and statistically 
significant differences where p < 0.05 marked with *. 
3 Results and discussion 
3.1 A uniform flow of protein requires mixing 
We initially used fluorescein dye, BSA-FITC conjugates and toxoid antigens to study the 
mixing and uniformity following direct reconstitution from filters in a simple reconstitution device. 
When imaged immediately after addition of ultrapure water to filter-dried fluorescein we found clear 
variations in intensity, in contrast to a bright and homogenous solution after vigorous mixing in the 
syringe (Fig. 1). This indicated that an additional mixing step should be incorporated to ensure 
vaccine is homogeneous on injection. Since mixing can occur in the syringe and needle during 
injection, and mixing is hard to quantify within the syringe body, an imaging chamber was made to 
measure fluorescence directly as the solution exits a needle suitable for vaccine administration (Fig. 
2A). Concentration was quantified within a uniform rectangular 20 µL chamber that was 2 mm high, 
10 mm long, with a thickness of 0.2 mm. Glass beads are used to mix anticoagulant into small volume 
blood samples in products such as Monovette®. In pilot tests, the effectiveness of adding a glass 
mixing bead, taken from a 1.2 mL Monovette®, and mixing by inversion was assessed with filter-
dried fluorescein dye. Inversion mixing with a glass bead gave a higher average fluorescence 
intensity and smaller standard deviation than inversion without the bead (Fig 2B), and the bead was 
therefore included in all subsequent experiments. Pilots also confirmed that dissolution from filters 
differs somewhat between the small molecule dye fluorescein vs protein, and so subsequent 
experiments used fluorescently labelled model protein. 
BSA-FITC was chosen as a model protein antigen and filter-dried onto cellulose and glass 
fibre squares. The release profile was assessed by measuring intensity of sequential 50µL volumes 
during injection through the chamber, after reconstituting with or without mixing. Both uniformity of 
intensity and overall yield were improved by mixing. Without mixing, there was significant variation 
both between replicates, and in the concentration delivered per unit volume during the injection 
period (Fig. 2C). Spikes in concentration were often detected for individual samples (for example in 
the first and/or last volume). This variation was reduced following mixing for any length of time, for 
both cellulose and glass filters (Fig. 2C-F). With glass filters, mixing also gave a clear increase in 
intensity. Although mixing also improved uniformity for cellulose filters, the fluorescence intensity 
was somewhat lower than glass filters, suggesting less efficient release. When mean and standard 
deviations were plotted, the reduction in variance and increase in released concentration were clear 
throughout the duration of the simulated injection (Fig. 2G). Whilst this study of a simple model 
protein antigen is highly informative, further study would be required to determine mixing efficacy for 
larger and more complex vaccine formulations including live attenuated vaccines which have been 
shown previously to be fully dry and achieve long-term thermostablisation after filter drying [13]. 
3.2 Maximal yields are obtained from glass filters mixed by inversion with glass bead 
Whilst the imaging system was ideal to determine uniformity in concentration as the injected volume 
passes out of the needle, and showed that variation was eliminated by mixing, it was important to 
determine independently the overall protein yield and determine if the apparent increase in 
concentration following mixing could be confirmed. The entire 500µl injection was therefore 
withdrawn from the reservoir, and protein yield measured. This clearly showed that the imaging 
system underestimated the increase in protein release following mixing, and also confirmed that the 
best yield was achieved by a combination of glass filters and mixing (Fig 3A). No further benefit was 
seen increasing mixing time above 1 minute. These observations were confirmed by absorbance 
measurements to quantify fluorescein concentration in bulk solutions recovered after complete 
injection. Likewise, when calibrated against standard concentrations imaged in the same chamber, 
similar total concentrations were estimated from the fluorescent imaging chamber to that found by 
bulk protein determination (data not shown). This validated the findings from the fluorescent imaging 
system, demonstrating that direct visulisation of mixing following reconstitution can be a valuable 
tool to optimize the uniformity of vaccine delivered from novel formulations and/or injection devices. 
Protein antigens are typically weakly immunogenic without adjuvant; it was therefore important to 
assess the effect of the adjuvant on filter-dried protein release. After the fluorescent protein was 
adsorbed to aluminium hydroxide adjuvant using standard methodology, the same protein 
measurement procedure was performed and once again significantly lower protein concentration 
was recovered without mixing. The analytical reference in this experiment was known concentrations 
of protein adsorbed to alum, to ensure that the aluminium hydroxide was not interfering with protein 
determination assay. Again, a high yield of alum-adsorbed fluorescent protein was released with 
mixing by inversion with a glass bead (Fig 3B). Although a slightly low protein concentration was 
observed in the three-minute mixing group than a control filter that had not been dried permitting 
maximal reconstitution, no significant difference was found between this and control group. Whilst 
this suggested that alum adjuvant did not influence reconstitution of this specific model fluorescent 
protein, different vaccine antigens, adjuvants, and formulations will require individual optimization of 
mixing on reconstitution, using the systems developed here. 
3.4 Mixing is required for maximal recovery of low concentration filter-dried toxoid antigen 
Antigen concentration for some subunit vaccines is substantially lower than that used in the imaging 
studies, making it far more challenging to either visualize protein release or measure protein content 
directly. Toxoid vaccines are potent immunogens and so very low concentrations are formulated in 
diphtheria and tetanus vaccines (typically around 1 lf per dose), and the reference toxoid samples 
we used in this study were supplied with a high concentration of protein carrier, further complicating 
measurement. The low concentrations plus the presence of protein carrier made it challenging to 
label for direct imaging or to measure antigen concentration and uniformity by fluorescence or protein 
determination. Instead, we exploited sandwich immunoassays developed specifically for quantitation 
of antigenically intact toxoids for quality control. The high analytical sensitivity of sandwich ELISA 
permitted us to test toxoid concentrations at or below that required for human vaccine dose. A very 
low-dose diphtheria and tetanus combined toxoid vaccine prototype incorporating glass fiber filter-
dried antigen samples was prepared and tested and antigen content evaluated by sandwich ELISA. 
Significant variations in antigen content were found in the unmixed group for both diphtheria and 
tetanus toxoids (Fig. 4). Although an increased yield with lower sample-sample variation was 
observed with mixing, the yield was still substantially lower than that observed with BSA-FITC (Figs. 
3 and 4). Approximately 60-70% of total input antigen content was recovered after five minutes of 
mixing, compared to the control sample which was treated identically but without filter drying and 
diluted in ultrapure water to produce a 500 µL sample. One explanation was that at this very low 
concentration of antigen, significant protein was irreversibly adsorbed onto the glass fiber filter during 
drying, which could potentially be avoided by pre-blocking or addition of blocking excipients. Specific 
formulations must be designed for each and every antigen or vaccine developed, and the addition 
of excipients such as surfactants may reduce loss by adsorption onto glass bead, filter, or syringe. 
Likewise, adsorption of the toxoid onto alum adjuvant might overcome this challenge. Another 
possibility is that the drying and reconstitution process denatured part of the toxoid antigen, rendering 
it undetectable in the sandwich ELISA that is designed to recognize antigenically intact toxoid. 
However, the improved uniformity and increased yield with mixing confirmed our observations with 
high dose fluorescent model protein that mixing is important for uniformity and yield. 
3.5 Suitability of simple combined filter plus bead injection concept  
This demonstration of a need for mixing for both maximizing recovery and ensuring injected vaccine 
is uniform after reconstitution illustrated the value of our simple combination of filter-dried vaccine 
plus glass mixing bead within a syringe as a model system. Figure 1B shows clearly that both yield 
and uniformity are improved by addition of a glass bead when filters are mixed. However, significant 
optimization and modification would be required for this to be used as a complete vaccine delivery 
system. Firstly, the mixing bead prevents complete depression of the syringe plunger, leaving a 
significand dead volume. This could be avoided by use of custom syringe design. Secondly, design 
for manufacture is required to ensure cost-effective production and packaging, taking into account 
the need for sterile manufacture and aseptic processing. Thirdly, whilst glass mixing beads are safe 
for use within plastic Monovette® syringe, if glass syringe was required e.g. for moisture protection, 
a plastic bead would likely be required to avoid the risk of glass bead scratching the glass syringe 
internally. Finally, a major design aspect is protecting the dried dose from moisture whilst 
incorporating water for injection within a package for distribution. One option is for water-
impermeable packaging (e.g. foil sealed pouch) for the dried vaccine, plus completely separate water 
for injection. Alternatively, if a single device combines dried vaccine with water for injection, water-
impermeable materials will be required to prevent water vapour penetrating the chamber where the 
filter dried vaccine dose is stored. There are no reports of uniformity of injected dose and mixing 
achieved when using the separate filter chamber reported by Alcock et al [13], and the lack of design 
details for these devices prevents us speculating if a mixing bead could readily be incorporated within 
such a device. These engineering challenges must be solved for any such ‘all-in-one’ vaccine 
delivery system to be safe for human use. However, this simplified model system was not intended 
as a fully developed vaccine formulation, but proved an informative testbed to demonstrate the 
importance of the neglected area of mixing and uniformity following reconstitution from dried 
vaccines. 
 
4 Conclusions 
In conclusion, we suggest that direct reconstitution and injection of protein antigens from a sugar 
glass dried at ambient temperature onto a filter does not deliver a uniform solution, and may not be 
appropriate for vaccine injections. We observed fluctuations and inconsistency in fluorescence 
intensity in the unmixed solution both within the syringe barrel (Fig 1A) and on exiting the needle 
during simulated injection (Fig 2). In contrast, after even 1 minute of mixing by inversion with a glass 
mixing bead a decreased standard deviation of solution exiting the needle was achieved, combined 
with an increase in protein antigen yield (Fig 2-4). This observation suggests that efficiency of mixing 
and uniformity of delivered dose should be evaluated for ‘all-in-one’ vaccine delivery devices that 
directly reconstitute filter-dried vaccine during injection; whilst the thermostability of these 
formulations has been thoroughly investigated [13] our findings here strongly suggest it is vital to 
ensure that this thermostability is matched with uniform and reliable reconstitution to avoid possible 
variation in efficacy in vivo. Surprisingly, adsorption onto alum adjuvant had no measurable effect 
on reconstitution and recovery of our model antigen (fluorescently labelled BSA). Recovery of toxoids 
dried at very low concentrations (representative of some potent human vaccines) was however lower 
than yields of fluorescently labelled BSA dried in microgram quantities, even with mixing. This 
suggested that each vaccine requires individual optimization to ensure effective recovery. We found 
a 2 ml disposable syringe can be used as a simple and low-cost housing for filter-dried vaccine, if a 
3 mm glass bead is included and the device is mixed by inversion following addition of water for 
reconstitution. This simple single unit device would permit simpler reconstitution and distribution than 
conventional vial lyophilized doses. However, significant further engineering and design-for-
manufacture is now required, combined with full evaluation of vaccine delivery efficacy in vivo, before 
this simple unit could be utilized. This pilot investigation suggests that reconstitution dynamics should 
be scrutinized for all single-injection devices intended to exploit direct reconstitution of thermostable 
dried vaccines.  
FIGURE LEGENDS 
Figure 1: Lack of uniformity of reconstituted fluorescein solution without mixing. 10µL 1mM 
sodium fluorescein was dried onto filters, and placed in the barrel of a 2 ml syringe (A) and imaged 
as 0.5 ml of ultrapure water was added (B). The syringe was then mixed by vigorous shaking, 
showing uniform fluorescence when well mixed (C).  
Figure 2: Mixing by inversion with glass bead gives uniform delivery at needle exit of model 
protein antigen from filter-dried model vaccine dose. A Diagram and example image of injection 
apparatus to measure protein concentration at needle exit during injection. B Effect of glass bead 
on mixing for sodium fluorescein. C-F Three individual replicate plots of BSA-FITC intensity at needle 
exit during 500µL injection from cellulose and glass filters with no mixing (C) or the indicated duration 
of inversion (D-F). G Comparison of mean and standard deviation of triplicates showing increased 
intensity and reduced variance with mixing vs no mixing. Error bars indicate +/- standard deviation 
of three replicate tests. 
Figure 3: Mixing increases yield from filter-dried model protein antigen. A The entire 500 µL 
volume imaged in Fig 2 was collected for BSA-FITC samples, and antigen yield measured by protein 
determination. B BSA-FITC was adsorbed onto alum antigen and dried onto glass filters, followed 
by assembly into prototype single-injection devices and reconstitution with or without mixing as 
indicated. Total antigen yield was measured in bulk 500 µL volume by protein determination. The 
line indicates maximal possible recovery and is the protein concentration from a control non-dried 
sample of BSA-FITC diluted directly into 500 µL alongside filter reconstitution. Bars indicate mean 
and error bars 1 standard deviation of three independent replicates. * indicates statistically significant 
differences (p<0.05) calculated using a student T-test. 
Figure 4: Mixing increases yield and reduces variability of release of low dose toxoid antigen, 
but with lower recovery. 10µL of a 2 lf/mL diptheria and tetanus toxoid mixture was dried per filter. 
This dose was the lowest concentration that permits quantitative measurement of release by 
sandwich ELISA, at this concentration a human vaccine dose would be 0.5mL. Each bar presents 
mean and standard deviation of triplicate ELISA measurements for one syringe containing 2 filters 
plus a mixing bead. The control sample is an identical filter plus 10 µL toxoid solution, which was not 
dried but directly diluted to 500 µL in parallel; the theoretical maximum concentration with complete 
release would be 0.08 lf/mL. 
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